Evidence map›Paper›PMID 37001602›Full record

Trial reportKidney international2023

Association of polygenic scores with chronic kidney disease phenotypes in a longitudinal study of older adults.

Andrew Bakshi, Julia Jefferis, Rory Wolfe, James B Wetmore, John J McNeil, Anne M Murray, Kevan R Polkinghorne, Andrew J Mallett, Paul Lacaze

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Kidney international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Polygenic risk, aspirin, and primary prevention of coronary artery disease.European heart journal. Cardiovascular pharmacotherapy · 2025
    Trial
  2. Review
  3. Article
  4. Signals within Complexity: Diabetes Genetic Heterogeneity and Clinical Outcomes in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Risk-directed management of chronic kidney disease.Nature reviews. Nephrology · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Review
  15. The Role of Genetic Testing in Adult CKD.Journal of the American Society of Nephrology : JASN · 2024
    Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Andrew BakshiSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Julia JefferisDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Rory WolfeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
James B WetmoreChronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA; Division of Nephrology, Hennepin Healthcare, Minneapolis, Minnesota, USA.
John J McNeilSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Anne M MurrayDepartment of Medicine, Geriatric Division, Hennepin Healthcare, Minneapolis, Minnesota, USA; Berman Centre for Clinical Research, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA; Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA; Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
Kevan R PolkinghorneSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia; Department of Nephrology, Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia.
Andrew J MallettInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia; Department of Renal Medicine, Townsville University Hospital, Douglas, Queensland, Australia; College of Medicine and Dentistry, James Cook University, Douglas, Queensland, Australia. Electronic address: Andrew.mallett@health.qld.gov.au.
Paul LacazeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Electronic address: paul.lacaze@monash.edu.
Monash University · AUHennepin Healthcare Research Institute · USMonash Health · AUPrincess Alexandra Hospital · AUThe University of Queensland · AUUniversity of Minnesota · US

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682
6 · The paper itself

Abstract

Risk of chronic kidney disease (CKD) is influenced by environmental and genetic factors and increases sharply in individuals 70 years and older. Polygenic scores (PGS) for kidney disease-related traits have shown promise but require validation in well-characterized cohorts. Here, we assessed the performance of recently developed PGSs for CKD-related traits in a longitudinal cohort of healthy older individuals enrolled in the Australian ASPREE randomized controlled trial of daily low-dose aspirin with CKD risk at baseline and longitudinally. Among 11,813 genotyped participants aged 70 years or more with baseline eGFR measures, we tested associations between PGSs and measured eGFR at baseline, clinical phenotype of CKD, and longitudinal rate of eGFR decline spanning up to six years of follow-up per participant. A PGS for eGFR was associated with baseline eGFR, with a significant decrease of 3.9 mL/min/1.73m

Indexed as

Renal Insufficiency, ChronicAustraliaCross-Sectional StudiesDisease ProgressionGlomerular Filtration RateHumansLongitudinal StudiesPhenotypechronic kidney diseasegeriatric nephrologypolygenic risk score

Identifiers

PMID37001602
PMCPMC10200771
OpenAlexW4361297504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.